For Healthcare Professionals

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

clipboard-pencil

About the study

The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. Have body mass index (BMI) equal to or above the 95th percentile for age and sex (on age and gender-specific growth chart for diagnosis of obesity) with at least 2 of the following predefined weight-related comorbidities: hypertension, prediabetes and hypertriglyceridemia.
  2. Have history of at least 1 self-reported unsuccessful dietary effort to lose weight.
  3. Are capable of giving signed informed consent by a legal representative or assent by a study participant (when applicable).

EXCLUSION CRITERIA

Exclusion Criteria:

* Have undergone or plan to undergo a weight reduction procedure during the study, such as, but not limited to

  1. gastric bypass
  2. sleeve gastrectomy
  3. restrictive bariatric surgery, such as Lap-Band gastric banding, or
  4. any other procedure intended to result in weight reduction.
  5. Have a self-reported, or by parent or legal guardian where applicable, decrease in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records
  6. Have type 1 diabetes or history of ketoacidosis, or hyperosmolar state
  7. Have type 2 diabetes or have a HbA1c > 6.4% at screening
  8. Have a history of chronic or acute pancreatitis
  9. Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 1-317-615-4559Email iconEmail Study Center

Study Details


Contition

Obesity,Weight Gain

Age

12 - 17

Phase

PHASE3

Participants Needed

300

Est. Completion Date

Jun 30, 2027

Treatment Type

INTERVENTIONAL


Sponsor

Eli Lilly and Company

ClinicalTrials.gov NCT Identifier

NCT06439277

Study Number

I8F-MC-GPIX

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to create a personal profile and 
receive news, resources, and alerts 
about clinical trials related to your conditions of interest.